{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:15:03Z","timestamp":1771650903964,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16H05441"],"award-info":[{"award-number":["16H05441"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16K10766"],"award-info":[{"award-number":["16K10766"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["18K09001"],"award-info":[{"award-number":["18K09001"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10147-019-01451-9","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T19:41:41Z","timestamp":1555443701000},"page":"1020-1029","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells"],"prefix":"10.1007","volume":"24","author":[{"given":"Azusa","family":"Hayano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8876-6673","authenticated-orcid":false,"given":"Yasuo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuya","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"1451_CR1","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/cncr.21481","volume":"104","author":"KS Panages","year":"2005","unstructured":"Panages KS, Elkin EB, DeAngelis LM et al (2005) Trends in survival from primary central nervous system lymphoma, 1975\u20131999: a population-based analysis. Cancer 104:2466\u20132472","journal-title":"Cancer"},{"key":"1451_CR2","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(11)61346-9","volume":"379","author":"D Ricard","year":"2012","unstructured":"Ricard D, Idbaih A, Ducray F et al (2012) Primary brain tumours in adults. Lancet 379:1984\u20131996","journal-title":"Lancet"},{"key":"1451_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820","journal-title":"Acta Neuropathol"},{"key":"1451_CR4","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","volume":"374","author":"AJ Ferreri","year":"2009","unstructured":"Ferreri AJ, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512\u20131520","journal-title":"Lancet"},{"key":"1451_CR5","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/S1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1136\u20131147","journal-title":"Lancet Oncol"},{"key":"1451_CR6","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","volume":"31","author":"PG Morris","year":"2013","unstructured":"Morris PG, Correa DD, Yahalom J et al (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31:3971\u20133979","journal-title":"J Clin Oncol"},{"key":"1451_CR7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/sj.bjc.6690083","volume":"9","author":"M Reni","year":"1999","unstructured":"Reni M, Ferreri AJ, Villa E (1999) Second-line treatment for primary central nervous system lymphoma. Br J Cancer 9:530\u2013534","journal-title":"Br J Cancer"},{"key":"1451_CR8","doi-asserted-by":"publisher","first-page":"22970","DOI":"10.1074\/jbc.C115.671123","volume":"290","author":"D Rushworth","year":"2015","unstructured":"Rushworth D, Mathews A, Alpert A et al (2015) Dihydrofolate reductase and thymidylate synthase transgenes resistant to methotrexate interact to permit novel transgene regulation. J Biol Chem 290:22970\u201322976","journal-title":"J Biol Chem"},{"key":"1451_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1083\/jcb.201604085","volume":"214","author":"KR Mattaini","year":"2016","unstructured":"Mattaini KR, Sullivan MR, Vander Heiden MG (2016) The importance of serine metabolism in cancer. J Cell Biol 214:249\u2013257","journal-title":"J Cell Biol"},{"key":"1451_CR10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1056\/NEJM199610033351408","volume":"335","author":"R Gorlick","year":"1996","unstructured":"Gorlick R, Goker E, Trippett T et al (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041\u20131048","journal-title":"N Engl J Med"},{"issue":"47","key":"1451_CR11","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.1038\/sj.onc.1206946","volume":"22","author":"R Zhao","year":"2003","unstructured":"Zhao R, Goldman ID (2003) Resistance to antifolates. Oncogene 22(47):7431\u20137457","journal-title":"Oncogene"},{"key":"1451_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10637-005-4541-1","volume":"24","author":"J Walling","year":"2006","unstructured":"Walling J (2006) From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Investig New Drugs 24:37\u201377","journal-title":"Investig New Drugs"},{"key":"1451_CR13","doi-asserted-by":"publisher","first-page":"5700","DOI":"10.1002\/cncr.25301","volume":"116","author":"G Jin","year":"2010","unstructured":"Jin G, Huang J, Hu Z et al (2010) Genetic variants in one-carbon metabolism-related genes contribute to NSCLC prognosis in a Chinese population. Cancer 116:5700\u20135709","journal-title":"Cancer"},{"key":"1451_CR14","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","volume":"194","author":"RE Davis","year":"2001","unstructured":"Davis RE, Brown KD, Siebenlist U et al (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861\u20131874","journal-title":"J Exp Med"},{"key":"1451_CR15","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1158\/0008-5472.CAN-06-3254","volume":"67","author":"SJ Strauss","year":"2007","unstructured":"Strauss SJ, Higginbottom K, J\u00fcliger S et al (2007) The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 67:2783\u20132790","journal-title":"Cancer Res"},{"key":"1451_CR16","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/modpathol.2014.34","volume":"27","author":"L Odqvist","year":"2014","unstructured":"Odqvist L, Montes-Moreno S, S\u00e1nchez-Pacheco RE et al (2014) NFkappaB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Mod Pathol 27:1331\u20131337","journal-title":"Mod Pathol"},{"key":"1451_CR17","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609\u20132617","journal-title":"N Engl J Med"},{"key":"1451_CR18","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS et al (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867\u20134874","journal-title":"J Clin Oncol"},{"key":"1451_CR19","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","volume":"113","author":"K Dunleavy","year":"2009","unstructured":"Dunleavy K, Pittaluga S, Czuczman MS et al (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113:6069\u20136076","journal-title":"Blood"},{"key":"1451_CR20","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1002\/cncr.24518","volume":"115","author":"V Ribrag","year":"2009","unstructured":"Ribrag V, Gisselbrecht C, Haioun C et al (2009) Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 115:4540\u20134546","journal-title":"Cancer"},{"key":"1451_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","volume":"29","author":"J Ruan","year":"2011","unstructured":"Ruan J, Martin P, Furman RR et al (2011) Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 29:690\u2013697","journal-title":"J Clin Oncol"},{"key":"1451_CR22","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1182\/blood-2015-03-632430","volume":"126","author":"F Offner","year":"2015","unstructured":"Offner F, Samoilova O, Osmanov E et al (2015) Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood 126:1893\u20131901","journal-title":"Blood"},{"key":"1451_CR23","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","volume":"35","author":"JP Leonard","year":"2017","unstructured":"Leonard JP, Kolibaba KS, Reeves JA et al (2017) Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol 35:3538\u20133546","journal-title":"J Clin Oncol"},{"key":"1451_CR24","doi-asserted-by":"publisher","first-page":"40752","DOI":"10.1038\/srep40752","volume":"7","author":"L Huang","year":"2017","unstructured":"Huang L, Jiang Y, Chen Y (2017) Predicting drug combination index and simulating the network-regulation dynamics by mathematical modeling of drug-targeted EGFR-ERK signaling pathway. Sci Rep 7:40752","journal-title":"Sci Rep"},{"key":"1451_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402\u2013408","journal-title":"Methods"},{"key":"1451_CR26","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1021\/bi4005182","volume":"52","author":"S Connelly","year":"2013","unstructured":"Connelly S, DeMartino JK, Boger DL et al (2013) Biological and structural evaluation of 10R- and 10S-methylthio-DDACTHF reveals a new role for sulfur in inhibition of glycinamide ribonucleotide transformylase. Biochemistry 52:5133\u20135144","journal-title":"Biochemistry"},{"key":"1451_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0305-7372(77)80007-8","volume":"4","author":"WA Bleyer","year":"1977","unstructured":"Bleyer WA (1977) Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 4:87\u2013101","journal-title":"Cancer Treat Rev"},{"key":"1451_CR28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1056\/NEJM198311033091805","volume":"309","author":"J Jolivet","year":"1983","unstructured":"Jolivet J, Cowan H, Curt A et al (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094\u20131104","journal-title":"N Engl J Med"},{"key":"1451_CR29","doi-asserted-by":"crossref","first-page":"9720","DOI":"10.1016\/S0021-9258(17)39298-0","volume":"260","author":"CJ Allegra","year":"1985","unstructured":"Allegra CJ, Chabner BA, Drake JC et al (1985) Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260:9720\u20139726","journal-title":"J Biol Chem"},{"key":"1451_CR30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1172\/JCI112088","volume":"76","author":"BA Chabner","year":"1985","unstructured":"Chabner BA, Allegra CJ, Curt GA et al (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Investig 76:907\u2013912","journal-title":"J Clin Investig"},{"key":"1451_CR31","first-page":"274","volume":"9","author":"E G\u00f6ker","year":"1995","unstructured":"G\u00f6ker E, Kheradpour A, Waltham M et al (1995) Acute monocytic leukemia: a myeloid leukemia subset that may be sensitive to methotrexate. Leukemia 9:274\u2013276","journal-title":"Leukemia"},{"key":"1451_CR32","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood.V85.2.500.500","volume":"85","author":"LH Matherly","year":"1995","unstructured":"Matherly LH, Taub JW, Ravindranath Y et al (1995) Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 85:500\u2013509","journal-title":"Blood"},{"key":"1451_CR33","doi-asserted-by":"publisher","first-page":"e0170186","DOI":"10.1371\/journal.pone.0170186","volume":"12","author":"V Mpakou","year":"2017","unstructured":"Mpakou V, Papadavid E, Kontsioti F et al (2017) Apoptosis induction and gene expression profile alterations of cutaneous T-cell lymphoma cells following their exposure to bortezomib and methotrexate. PLoS One 12:e0170186","journal-title":"PLoS One"},{"key":"1451_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-2141.2010.08315.x","volume":"151","author":"JE Romaguera","year":"2010","unstructured":"Romaguera JE, Fayad LE, McLaughlin P et al (2010) Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol 151:47\u201353","journal-title":"Br J Haematol"},{"key":"1451_CR35","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cncr.31361","volume":"124","author":"JE Romaguera","year":"2018","unstructured":"Romaguera JE, Wang M, Feng L et al (2018) Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer 124:2561\u20132569","journal-title":"Cancer"},{"key":"1451_CR36","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1158\/0008-5472.CAN-08-3735","volume":"69","author":"DL Hodge","year":"2009","unstructured":"Hodge DL, Yang J, Buschman MD et al (2009) Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias. Cancer Res 69:3986\u20133994","journal-title":"Cancer Res"},{"key":"1451_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/OTT.S115892","volume":"10","author":"C Bagacean","year":"2016","unstructured":"Bagacean C, Tempescul A, Patiu M et al (2016) Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report. OncoTargets Ther 10:31\u201334","journal-title":"OncoTargets Ther"},{"key":"1451_CR38","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3109\/10428194.2014.981172","volume":"56","author":"N Johnson-Farley","year":"2015","unstructured":"Johnson-Farley N, Veliz J, Bhagavathi S et al (2015) ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in \"double hit\" lymphoma cells. Leuk Lymphoma 56:2146\u20132152","journal-title":"Leuk Lymphoma"},{"key":"1451_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1871524914999140818111514","volume":"14","author":"A Gozzetti","year":"2014","unstructured":"Gozzetti A, Cerase A (2014) Novel agents in CNS myeloma treatment. Cent Nerv Syst Agents Med Chem 14:23\u201327","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"1451_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bjh.15233","volume":"181","author":"GJL Kaspers","year":"2018","unstructured":"Kaspers GJL, Niewerth D, Wilhelm BAJ et al (2018) An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. Br J Haematol 181:523\u2013527","journal-title":"Br J Haematol"},{"key":"1451_CR41","first-page":"1","volume":"15","author":"W Wang","year":"2019","unstructured":"Wang W, Swenson S, Cho HY et al (2019) Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models. J Neurosurg 15:1\u20139","journal-title":"J Neurosurg"},{"key":"1451_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.nbd.2016.01.008","volume":"88","author":"E Foran","year":"2016","unstructured":"Foran E, Kwon DY, Nofziger JH et al (2016) CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis 88:118\u2013124","journal-title":"Neurobiol Dis"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01451-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01451-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01451-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T02:51:19Z","timestamp":1663296679000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01451-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1451"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01451-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,16]]},"assertion":[{"value":"17 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no conflict of financial and non-financial interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}